Refining basal insulin therapy: what have we learned in the age of analogues?
Diabetes/Metabolism Research and Reviews2007Vol. 23(6), pp. 441–454
Citations Over TimeTop 10% of 2007 papers
Abstract
Scrutiny of trials involving glargine and detemir has increased our understanding of how best to dose basal insulins. An individualized approach is still necessary however, and several questions remain that require further research.
Related Papers
- → Morning Dosing of Once-daily Glaucoma Medication is More Convenient and May Lead to Greater Adherence Than Evening Dosing(2011)12 cited
- → Cost-Effectiveness Analysis of Insulin Detemir Versus Insulin Neutral Protamine Hagedorn (Nph) In Patients With Type 1 Diabetes Mellitus In Spain(2014)1 cited
- → Comparison of morning versus evening dosing with a new once-daily oral theophylline formulation(1985)32 cited
- → Faculty Opinions recommendation of Morning dosing of once-daily glaucoma medication is more convenient and may lead to greater adherence than evening dosing.(2013)1 cited
- → PDB56 THE IMPACT OF STARTING INSULIN GLARGINE VERSUS INSULIN DETEMIR ON QUALITY OF LIFE (QOL) AND TREATMENT SATISFACTION (TS) IN PATIENTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON ORAL GLUCOSE-LOWERING DRUGS (OGLDS)(2009)